Decreased periprosthetic bone loss in patients treated with clodronate: A 1-year randomized controlled study

C. Trevisan, S. Ortolani, P. Romano, G. Isaia, L. Agnese, D. Dallari, G. Grappiolo, R. Cherubini, L. Massari, G. Bianchi

Research output: Contribution to journalArticle

Abstract

The efficacy of clodronate to reduce bone loss around uncemented stems after total hip arthroplasty (THA) was evaluated. Ninety-one patients operated with uncemented THA were randomized to receive either intramuscular clodronate at a dose of 100 mg weekly for 12 months or no treatment. Periprosthetic and contralateral bone mineral density (BMD) scans were performed and biochemical markers of bone turnover measured at baseline and at 3, 6, and 12 months. At month 12, with the exception of Gruen zones 4 and 5, patients treated with clodronate showed less bone loss at all zones, reaching statistical significance (P <0.05) in Gruen zones 2 and 6 (difference of 6.6 and 5.9%, respectively). Analysis of data according to gender revealed sex-related differences in bone loss and efficacy of treatment. After 12 months, the difference in bone loss between treated and untreated women in five out of seven Gruen zones ranged from 6.2 to 13.3% (SS at zones 2 and 6), whereas comparison between treated and untreated men showed no BMD differences in all zones (P > 0.05). Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMD changes. A 1-year treatment with intramuscular clodronate determined a significant reduction of bone loss after THA. This was mainly attributed to its greater efficacy in the female population, which is at higher risk for bone loss. This observation suggests the need for the characterization of high-risk subjects as potential candidates for prevention strategies.

Original languageEnglish
Pages (from-to)436-446
Number of pages11
JournalCalcified Tissue International
Volume86
Issue number6
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Clodronic Acid
Bone and Bones
Arthroplasty
Hip
Bone Density
Biomarkers
Bone Remodeling
Therapeutics
Population

Keywords

  • Bisphosphonate
  • Bone mineral density
  • Clodronate
  • Total hip arthroplasty
  • Uncemented prosthesis

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Decreased periprosthetic bone loss in patients treated with clodronate : A 1-year randomized controlled study. / Trevisan, C.; Ortolani, S.; Romano, P.; Isaia, G.; Agnese, L.; Dallari, D.; Grappiolo, G.; Cherubini, R.; Massari, L.; Bianchi, G.

In: Calcified Tissue International, Vol. 86, No. 6, 06.2010, p. 436-446.

Research output: Contribution to journalArticle

Trevisan, C, Ortolani, S, Romano, P, Isaia, G, Agnese, L, Dallari, D, Grappiolo, G, Cherubini, R, Massari, L & Bianchi, G 2010, 'Decreased periprosthetic bone loss in patients treated with clodronate: A 1-year randomized controlled study', Calcified Tissue International, vol. 86, no. 6, pp. 436-446. https://doi.org/10.1007/s00223-010-9356-1
Trevisan, C. ; Ortolani, S. ; Romano, P. ; Isaia, G. ; Agnese, L. ; Dallari, D. ; Grappiolo, G. ; Cherubini, R. ; Massari, L. ; Bianchi, G. / Decreased periprosthetic bone loss in patients treated with clodronate : A 1-year randomized controlled study. In: Calcified Tissue International. 2010 ; Vol. 86, No. 6. pp. 436-446.
@article{c17e2913748e44c796f8c515d4f245bd,
title = "Decreased periprosthetic bone loss in patients treated with clodronate: A 1-year randomized controlled study",
abstract = "The efficacy of clodronate to reduce bone loss around uncemented stems after total hip arthroplasty (THA) was evaluated. Ninety-one patients operated with uncemented THA were randomized to receive either intramuscular clodronate at a dose of 100 mg weekly for 12 months or no treatment. Periprosthetic and contralateral bone mineral density (BMD) scans were performed and biochemical markers of bone turnover measured at baseline and at 3, 6, and 12 months. At month 12, with the exception of Gruen zones 4 and 5, patients treated with clodronate showed less bone loss at all zones, reaching statistical significance (P <0.05) in Gruen zones 2 and 6 (difference of 6.6 and 5.9{\%}, respectively). Analysis of data according to gender revealed sex-related differences in bone loss and efficacy of treatment. After 12 months, the difference in bone loss between treated and untreated women in five out of seven Gruen zones ranged from 6.2 to 13.3{\%} (SS at zones 2 and 6), whereas comparison between treated and untreated men showed no BMD differences in all zones (P > 0.05). Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMD changes. A 1-year treatment with intramuscular clodronate determined a significant reduction of bone loss after THA. This was mainly attributed to its greater efficacy in the female population, which is at higher risk for bone loss. This observation suggests the need for the characterization of high-risk subjects as potential candidates for prevention strategies.",
keywords = "Bisphosphonate, Bone mineral density, Clodronate, Total hip arthroplasty, Uncemented prosthesis",
author = "C. Trevisan and S. Ortolani and P. Romano and G. Isaia and L. Agnese and D. Dallari and G. Grappiolo and R. Cherubini and L. Massari and G. Bianchi",
year = "2010",
month = "6",
doi = "10.1007/s00223-010-9356-1",
language = "English",
volume = "86",
pages = "436--446",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Decreased periprosthetic bone loss in patients treated with clodronate

T2 - A 1-year randomized controlled study

AU - Trevisan, C.

AU - Ortolani, S.

AU - Romano, P.

AU - Isaia, G.

AU - Agnese, L.

AU - Dallari, D.

AU - Grappiolo, G.

AU - Cherubini, R.

AU - Massari, L.

AU - Bianchi, G.

PY - 2010/6

Y1 - 2010/6

N2 - The efficacy of clodronate to reduce bone loss around uncemented stems after total hip arthroplasty (THA) was evaluated. Ninety-one patients operated with uncemented THA were randomized to receive either intramuscular clodronate at a dose of 100 mg weekly for 12 months or no treatment. Periprosthetic and contralateral bone mineral density (BMD) scans were performed and biochemical markers of bone turnover measured at baseline and at 3, 6, and 12 months. At month 12, with the exception of Gruen zones 4 and 5, patients treated with clodronate showed less bone loss at all zones, reaching statistical significance (P <0.05) in Gruen zones 2 and 6 (difference of 6.6 and 5.9%, respectively). Analysis of data according to gender revealed sex-related differences in bone loss and efficacy of treatment. After 12 months, the difference in bone loss between treated and untreated women in five out of seven Gruen zones ranged from 6.2 to 13.3% (SS at zones 2 and 6), whereas comparison between treated and untreated men showed no BMD differences in all zones (P > 0.05). Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMD changes. A 1-year treatment with intramuscular clodronate determined a significant reduction of bone loss after THA. This was mainly attributed to its greater efficacy in the female population, which is at higher risk for bone loss. This observation suggests the need for the characterization of high-risk subjects as potential candidates for prevention strategies.

AB - The efficacy of clodronate to reduce bone loss around uncemented stems after total hip arthroplasty (THA) was evaluated. Ninety-one patients operated with uncemented THA were randomized to receive either intramuscular clodronate at a dose of 100 mg weekly for 12 months or no treatment. Periprosthetic and contralateral bone mineral density (BMD) scans were performed and biochemical markers of bone turnover measured at baseline and at 3, 6, and 12 months. At month 12, with the exception of Gruen zones 4 and 5, patients treated with clodronate showed less bone loss at all zones, reaching statistical significance (P <0.05) in Gruen zones 2 and 6 (difference of 6.6 and 5.9%, respectively). Analysis of data according to gender revealed sex-related differences in bone loss and efficacy of treatment. After 12 months, the difference in bone loss between treated and untreated women in five out of seven Gruen zones ranged from 6.2 to 13.3% (SS at zones 2 and 6), whereas comparison between treated and untreated men showed no BMD differences in all zones (P > 0.05). Median percent changes in serum levels of markers of bone metabolism by gender were consistent with BMD changes. A 1-year treatment with intramuscular clodronate determined a significant reduction of bone loss after THA. This was mainly attributed to its greater efficacy in the female population, which is at higher risk for bone loss. This observation suggests the need for the characterization of high-risk subjects as potential candidates for prevention strategies.

KW - Bisphosphonate

KW - Bone mineral density

KW - Clodronate

KW - Total hip arthroplasty

KW - Uncemented prosthesis

UR - http://www.scopus.com/inward/record.url?scp=77953232096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953232096&partnerID=8YFLogxK

U2 - 10.1007/s00223-010-9356-1

DO - 10.1007/s00223-010-9356-1

M3 - Article

C2 - 20390409

AN - SCOPUS:77953232096

VL - 86

SP - 436

EP - 446

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 6

ER -